However, the following points are recommendations for clinicians by the ACR COVID-19 Clinical Guidance Task Force:
- Hydroxychloroquine or chloroquine (HCQ/CQ), sulfasalazine (SSZ), methotrexate (MTX), leflunomide (LEF), immunosuppressants (e.g., tacrolimus, cyclosporine, mycophenolate mofetil, azathioprine), biologics, Janus kinase (JAK) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) may be continued (this includes patients with giant cell arteritis with an indication, in whom IL-6 inhibitors should be continued, if available).
- Denosumab may still be given, extending dosing intervals to no longer than every 8 months, if necessary to minimize healthcare encounters.
- For patients with a history of vital organ-threatening rheumatic disease, immunosuppressants should not be dose-reduced.
Source: ACR COVID-19 Clinical Guidance Task Force